Publications
Knowledge generated at IrsiCaixa is shared with the scientific community through the publication of articles in high impact scientific journals.
Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.
Herb-drug interaction between Echinacea purpurea and etravirine in HIV-infected patients.
HIV-1 capture and antigen presentation by dendritic cells: enhanced viral capture does not correlate with better T cell activation.
Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients.
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end-stage renal disease.
Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir.
Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.